Knowledge, attitude and practice toward liraglutide and semaglutide among endocrinology medical staff.
Sci Rep · 2025
Last updated 2026-05-28A study of 265 endocrinology medical staff found average scores of 11.77 out of 16 for knowledge, 39.30 out of 50 for attitude, and 27.70 out of 35 for practice regarding the drugs liraglutide and semaglutide. Higher knowledge scores were linked to better attitudes and practices, and better attitudes also improved practice scores.
AI summary of the abstract below.
| Journal | Sci Rep, 2025 |
|---|---|
| Citations | 1 |
| Molecules | semaglutide, liraglutide |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Semaglutide and liraglutide are commonly used to address metabolic disorders, but differ in usage, clinical efficacy and safety profiles. Endocrinology medical staff are crucial in ensuring the appropriate administration, but their knowledge, attitude, and practice (KAP) towards these medications have been underexplored. The study aimed to investigate their KAP toward liraglutide and semaglutide. A cross-sectional study was performed from September to December 2023 at the First People's Hospital of Jiujiang. Endocrinology medical staff completed a self-administered questionnaire for KAP assessment regarding liraglutide and semaglutide. A total of 265 participants were enrolled (mean age: 36.31 ± 8.17 years old), including 134 (50.57%) males. The average scores were as follows: knowledge 11.77 ± 3.37 (range: 0-16), attitude 39.30 ± 4.61 (range: 10-50), and practice 27.70 ± 5.52 (range: 7-35). The structural equation model (SEM) showed that knowledge significantly influenced attitude (β = 0.976, P < 0.001) and practice (β = 1.289, P < 0.001). Additionally, attitude had a significant effect on practice (β = 0.627, P < 0.001). This study revealed deficiencies in the KAP scores among endocrinology medical staff, emphasizing the necessity for targeted strategies to improve professional proficiency with liraglutide and semaglutide.
Verbatim abstract via PubMed 40185826 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.